Prognostic Value of Stem Cell Related Markers

This study has been withdrawn prior to enrollment.
(no finance)
Sponsor:
Information provided by:
The Baruch Padeh Medical Center, Poriya
ClinicalTrials.gov Identifier:
NCT01265225
First received: December 21, 2010
Last updated: December 22, 2013
Last verified: December 2013
  Purpose

The goal of the investigators study is to identify a prognostic marker that will evaluate the probability of recurrence in patients with stage 0-II breast cancer following surgery to remove the tumor.


Condition
Breast Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Official Title: Prognostic Value of Stem Cell Related Markers CD24, CD44, CD326 and EPCR, for Predicting Breast Cancer Recurrence in Tumor Stages 0-II

Resource links provided by NLM:


Further study details as provided by The Baruch Padeh Medical Center, Poriya:

Enrollment: 0
Study Start Date: February 2011
Estimated Study Completion Date: April 2013
Estimated Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

100 tumor specimens from women with grade 0-11 ductal breast cancer

Criteria

Inclusion Criteria:

  • Ductal Carcinoma in Situ
  • DCIS + Microinvasion stages 1 or 11 without positive lymph nodes

Exclusion Criteria:

  • tumor specimen with higher than grade II
  • BRACA 1 or BRACA 2 mutation
  • Neoadjuvant chemotherapy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01265225

Locations
Israel
Baruch PMC
Poriya, Lower galilee, Israel, 15208
Sponsors and Collaborators
The Baruch Padeh Medical Center, Poriya
  More Information

No publications provided

Responsible Party: Dr. I. Schnirer, Baruch Padeh Poriya Medical Center
ClinicalTrials.gov Identifier: NCT01265225     History of Changes
Other Study ID Numbers: 10.CTIL
Study First Received: December 21, 2010
Last Updated: December 22, 2013
Health Authority: Israel: Ministry of Health

Keywords provided by The Baruch Padeh Medical Center, Poriya:
breast cancer stages 0-II

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on April 15, 2014